TOP > 外国特許検索 > MODIFICATION OF HELPER T CELL-INDUCING POLYPEPTIDE

MODIFICATION OF HELPER T CELL-INDUCING POLYPEPTIDE 新技術説明会

Foreign code F140007813
File No. S2012-0231-C0
Posted date 2014年1月8日
Country 世界知的所有権機関(WIPO)
International application number 2012JP082573
International publication number WO 2013089252
Date of international filing 平成24年12月14日(2012.12.14)
Date of international publication 平成25年6月20日(2013.6.20)
Priority data
  • 特願2011-273922 (2011.12.14) JP
Title MODIFICATION OF HELPER T CELL-INDUCING POLYPEPTIDE 新技術説明会
Abstract The invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using the same.
Outline of related art and contending technology BACKGROUND ART
In the immunity against tumors, CD8+ cytotoxic T lymphocytes (CTL: cytotoxic T lymphocyte) kill the tumor cells is a major role as an effector. In addition, CD4+ T helper cells (Th: helper T), in particular Th1 type Th cells is an effective anti-tumor immunity induction activity have been reported to be essential for the (non-patent document 1-4). The role of Th cells in anti-tumor immunity, a variety of reports on the far and, CTL differentiation, inducing the growth of (non-patent document 5), the antigen presenting cells (APC: antigen presenting cell), which is capable of activating CTL directly bring the, or an antigen cross-presentation by APC, activate CTL (non-patent document 6, 7), and the anti-apoptotic effect APC CTL (non-patent document 8, 9), the maintenance of cell proliferation and peripheral memory pool CD8T enlarged help function (non-patent document 10, 11), the infiltration of the tumor tissue of the induced CTL (non-patent document 12, 13) and the like are known.
Anti-tumor immunity using the method for the treatment of malignant tumors, a number of studies have been made. For example, to induce CTL HLA (human leukocyte antigen: human leukocyte antigen; those described later referred to as HLA in human MHC) class I-binding tumor antigen-specific polypeptide is used for immunotherapy, the polypeptide alone, or non-methylated deoxy CpG, Toll-like receptor ligand or co-administered with adjuvants such as Flt3, is performed. However, by such methods is, even CTL as an effector of growth XDECef is sufficiently hard, the therapeutic effect is limited. Also, as new anti-tumor immunotherapy, to induce CTL HLA class I-binding tumor antigen polypeptide, the cells induced Th HLA class II-binding tumor antigen immunotherapy using the polypeptide also has been studied. However, such a method can be to activate cells tumor antigen-specific Th is not limited to, instead, the controllability T cells suppress immunity to a tumor antigen (Treg) and induce, as a result of suppression of anti-tumor immunity (non-patent document 14) there is a concern. In particular in anti-tumor immunity is, in the body of the target self-antigen is a tumor antigen for naturally occurring, the components of the immune system is regarded as self-tumor antigens, normal, aggressive response which is less likely. This is because, in a living body to prevent self-reactive T cells included in the "self-tolerance" of the reactor by, and recognize self-antigens is immature T cells to respond strongly to lead to cell death still fresh, autologous antigen remains moderate, weak or suppressed T cells also react in some functional state. For this reason, by administering tumor antigen carelessly, Treg inducing, an immune response against tumors may highly possibly rather suppressed. In order to eliminate the likelihood of, the inventors have, in the past to induce CTL HLA class I-binding tumor antigen polypeptide, as an adjuvant, pertussis vaccine which had been non-tumor antigen and a third party antigen induces Th for pertussis bacteria, tumor antigen-specific CTL in a method of generating the registance, to induce anti-tumor immunity has succeeded in (Patent Document 1). In particular in that method the use of the pertussis whole - cell vaccines, type high CTL-inducing activity can be induced efficiently Th Th1 cells. However, for induction of tumor antigen-specific Th1 cells is, as described above the problem of controllability T cells, they are not yet reliable method of induction is in.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
  • Inventor
  • UDAKA, Keiko
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close